Author:
Chakravarty Jaya,Sundar Shyam,Chourasia Ankita,Singh Pallav Narayan,Kurle Swarali,Tripathy Srikanth P.,Chaturbhuj Devidas N,Rai Madhukar,Agarwal Amit Kumar,Mishra Rabindra Nath,Paranjape Ramesh S.
Funder
Centre Of Excellence, National AIDS Control Organization , India
HIV drug resistance database project ,Indian Council of Medical Research (ICMR), New Delhi
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. NACO: Annual report 2014–15. Department of AIDS Control, Ministry of Health and Family Welfare, Government of India.
2. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(8):510–8.
3. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53(4):500–6.
4. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929–38.
5. Patel D, Desai M, Shah AN, Dikshit RK. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res. 2013;4(4):215–20.